Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort
- PMID: 38233104
- DOI: 10.1136/ard-2023-224959
Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort
Abstract
Objectives: To investigate the prevalence of axial spondyloarthritis (axSpA) in patients with chronic back pain (CBP) of less than 2 years (2y) duration referred to the rheumatologist, the development of diagnosis over time, and patient characteristics of those developing definite (d-)axSpA over 2y.
Methods: We analysed the 2y data from SPondyloArthritis Caught Early, a European cohort of patients (<45 years) with CBP (≥3 months, ≤2y) of unknown origin. The diagnostic workup comprised evaluation of clinical SpA features, acute phase reactants, HLA-B27, radiographs and MRI (sacroiliac joints and spine), with repeated assessments. At each visit (baseline, 3 months, 1y and 2y), rheumatologists reported a diagnosis of axSpA or non-axSpA with level of confidence (LoC; 0-not confident at all to 10-very confident).
Main outcome: axSpA diagnosis with LoC≥7 (d-axSpA) at 2y.
Results: In 552 patients with CBP, d-axSpA was diagnosed in 175 (32%) at baseline and 165 (30%) at 2y. Baseline diagnosis remained rather stable: at 2y, baseline d-axSpA was revised in 5% of patients, while 8% 'gained' d-axSpA. Diagnostic uncertainty persisted in 30%. HLA-B27+ and baseline sacroiliitis imaging discriminated best 2y-d-axSpA versus 2y-d-non-axSpA patients. Good response to non-steroidal anti-inflammatory drugs and MRI-sacroiliitis most frequently developed over follow-up in patients with a new d-axSpA diagnosis. Of the patients who developed MRI-sacroiliitis, 7/8 were HLA-B27+ and 5/8 male.
Conclusion: A diagnosis of d-axSpA can be reliably made in nearly one-third of patients with CBP referred to the rheumatologist, but diagnostic uncertainty may persist in 5%-30% after 2y. Repeated assessments yield is modest, but repeating MRI may be worthwhile in male HLA-B27+ patients.
Keywords: Classification; Outcome and Process Assessment, Health Care; Spondylitis, Ankylosing.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MLM: none. SR: Research Grants—AbbVie, Galapagos, MSD, Novartis, Pfizer, UCB. Consultancy—AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sanofi, UCB. MvL: none. RS: none. RBML: Consultancy—AbbVie, Eli-Lilly, Janssen, Galapagos, Gilead, Novartis, Pfizer, UCB. Director of Rheumatology Consultancy BVD. MvdS: Speaker—Janssen, Novartis, UCB. Consultancy—Abbvie, Eli Lilly, Novartis, UCB. Research Grants:Janssen, Novartis, UCB. KMF: none. IJB: none. MvO: none. SE: Consultancy—AbbVie, Janssen, Novartis, and UCB. RR: Consultancy: Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, UCB, Amgen. DvdH: Consultancy—AbbVie, ArgenX, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, Takeda, UCB Pharma. Director of Imaging Rheumatology bv. FAvG: Research Grants -Novartis. Consultancy—MSD, AbbVie, Novartis and BMS.
Similar articles
-
Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts.Arthritis Res Ther. 2017 May 31;19(1):118. doi: 10.1186/s13075-017-1335-8. Arthritis Res Ther. 2017. PMID: 28569222 Free PMC article.
-
Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort.Ann Rheum Dis. 2017 Jun;76(6):1086-1092. doi: 10.1136/annrheumdis-2016-210119. Epub 2017 Jan 6. Ann Rheum Dis. 2017. PMID: 28062405
-
Quantification of bone marrow edema by MRI of the sacroiliac joints in patients diagnosed with axial spondyloarthritis: results from the ESPeranza cohort.Scand J Rheumatol. 2022 Sep;51(5):374-381. doi: 10.1080/03009742.2021.1946995. Epub 2021 Sep 2. Scand J Rheumatol. 2022. PMID: 34472387
-
[Identification of patients with axial spondylarthritis in primary care (AWARE study)].Z Rheumatol. 2019 Aug;78(6):568-576. doi: 10.1007/s00393-018-0550-2. Z Rheumatol. 2019. PMID: 31375960 Review. German.
-
Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities.Clin Rheumatol. 2019 Mar;38(3):625-634. doi: 10.1007/s10067-018-4397-3. Epub 2018 Dec 26. Clin Rheumatol. 2019. PMID: 30588555 Review.
Cited by
-
Baseline and 2-year differences in spinal symptoms and spinal and hip mobility in early axial spondyloarthritis and non-axial spondyloarthritis chronic back pain patients.RMD Open. 2024 Oct 26;10(4):e004713. doi: 10.1136/rmdopen-2024-004713. RMD Open. 2024. PMID: 39461873 Free PMC article.
-
Change in different classes of chronic back pain suspicious of axial spondyloarthritis: a latent transition analysis of the SPACE cohort.RMD Open. 2024 Sep 30;10(3):e004584. doi: 10.1136/rmdopen-2024-004584. RMD Open. 2024. PMID: 39349053 Free PMC article.
-
Progressive improvement in time to diagnosis in axial spondyloarthritis through an integrated referral and education system.Rheumatol Adv Pract. 2024 Aug 23;8(4):rkae102. doi: 10.1093/rap/rkae102. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 39282622 Free PMC article.
-
Artificial intelligence improves the diagnosis of human leukocyte antigen (HLA)-B27-negative axial spondyloarthritis based on multi-sequence magnetic resonance imaging and clinical features.Quant Imaging Med Surg. 2024 Aug 1;14(8):5845-5860. doi: 10.21037/qims-24-729. Epub 2024 Jul 30. Quant Imaging Med Surg. 2024. PMID: 39144059 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials